Jin Soo Lee

National Cancer Center Korea, Kōyō, Gyeonggi Province, South Korea

Are you Jin Soo Lee?

Claim your profile

Publications (204)825.61 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Injury in the dominant language hemisphere typically leads to agraphia, however we report a patient with agraphia after injury to the right angular gyrus. A 71-year-old Korean woman presented with the complaint of an inability to write for the last 7 days. The patient had been illiterate for most of her life, but had started learning to write Hangul, the Korean alphabet, at a welfare center 3 years ago. On language screening she was unable to write although she could read, and other language functions showed no abnormalities. Brain MRI showed acute infarction in the right angular gyrus. Her writing patterns displayed features of surface agraphia, indicative of phoneme-to-grapheme conversion with phonetic writing of targets. Additionally, she manifested visual errors. A functional MRI indicated that her left hemisphere was language dominant. This patient experienced agraphia resulting from pure impairment of visuo-constructive function after acute infarction in the right angular gyrus.
    Journal of Clinical Neuroscience 01/2015; · 1.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 64-year-old male patient diagnosed with amyotrophic lateral sclerosis 2 years ago was admitted with fever and chills. The patient had complex medical history and several indwelling catheters/tubes in his body. To identify the infection focus, Ga whole-body scintigraphy and SPECT/CT were obtained. Ga whole-body scintigraphy demonstrated focal Ga uptake in the lower pelvic cavity and the right kidney. Additional Ga SPECT/CT images were obtained, and it enabled characterization of these uptakes as infection of bladder stones that result in pyelitis.
    Clinical Nuclear Medicine 12/2014; · 2.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pneumonia and acute exacerbation of chronic illness are leading causes of influenza-related hospitalization. Therefore, influenza and pneumococcal vaccinations are strongly recommended for adults with comorbidities. Using a hospital-based influenza surveillance system, we performed a multicenter, prospective cohort study of patients visiting emergency rooms with influenza-like illness (ILI) during the influenza epidemic period in 2013-2014. Patients aged ≥ 19 years were enrolled, and clinical data was collected. Multivariate analyses were performed to estimate the effectiveness of influenza and pneumococcal vaccination in preventing pneumonia development and hospitalization. During study periods, 2,262 patients with ILI were registered. Among 2,217 patients with available vaccination records, 31.9% (707 patients) and 9.7% (216 patients) had received influenza and pneumococcal vaccines, respectively. Among patients who had been administered a pneumococcal vaccine, 94.4% had received the 23-valent polysaccharide vaccine (PPV23). The adjusted influenza vaccine effectiveness for preventing pneumonia development and hospitalization was 64.0% (95% confidence interval [CI] = 29% - 81%) and 35.0% (95% CI = 12% - 52%), respectively. Pneumococcal vaccination did not reduce pneumonia development or hospitalization. In conclusion, influenza rather than PPV23 vaccination may reduce pneumonia development and hospitalization in patients with preceding ILI. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
    Clinical and vaccine Immunology: CVI 12/2014; · 2.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background To investigate a prognostic role of gross tumor volume (GTV) changes on survival outcomes following concurrent chemoradiotherapy (CCRT) in stage III non-small-cell lung cancer (NSCLC) patients.Methods We enrolled 191 patients with stage III NSCLC from 2001 to 2009 undergoing definitive CCRT. The GTV of 157 patients was delineated at the planning CT prior to CCRT and with a follow-up CT 1 month after CCRT. We assessed the volumetric parameters of pre-treatment GTV (GTVpre) post-treatment GTV (GTVpost), and volume reduction ratio of GTV (VRR). The primary endpoint was overall survival (OS) and secondary endpoints were progression-free survival (PFS) and locoregional progression-free survival (LRPFS). The best cut-off value was defined as that which exhibited the maximum difference between the two groups.ResultsThe median follow-up duration was 52.7 months in surviving patients. Median survival, 3-year OS, PFS and LRPFS rates were 25.5 months, 36.4%, 23.0%, and 45.0%, respectively. The selected cut-off values were 50 cm3 for GTVpre , 20 cm3 for GTVpost , and 50% for VRR. The smaller GTVpre and GTVpost values were associated with better OS (p¿<¿0.001 and p¿=¿0.015) and PFS (p¿=¿0.001 and p¿=¿0.004), respectively, upon univariate analysis. The higher VRR of¿>¿50% was associated with a trend toward poorer OS (p¿=¿0.004) and PFS (p¿=¿0.054). Upon multivariate analysis, smaller GTVpre indicated significantly improved OS (p¿=¿0.001), PFS (p¿=¿0.013) and LRPFS (p¿=¿0.002), while smaller GTVpost was marginally significant for PFS (p¿=¿0.086). Higher VRR was associated with a trend toward poorer OS (p¿=¿0.075).Conclusions In patients with stage III NSCLC undergoing definitive CCRT, GTVpre was an independent prognostic factor of survival. Notably, improved outcome was not correlated with higher VRR after short-term follow-up with CT alone.
    Radiation Oncology 12/2014; 9(1):283. · 2.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Disease flare-up after discontinuing epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been considered as a critical issue in lung cancer patients who have experienced radiologic progression after showing initial durable response. This is a case of systemic nocardiosis that occurred after chronic steroid use for radionecrosis from stereotactic radiosurgery. It was initially thought as a disease flare-up after stopping EGFR-TKI.
    Tuberculosis and Respiratory Diseases 12/2014; 77(6):271-3.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The clinical profile of EGFR-mutant lung cancer carrying sporadic primary EGFR T790M mutation was similar to that of classic EGFR-mutant lung cancer, except for an overrepresentation of never-smokers and brain metastasis. Additionally, any cytotoxic drugs showed no increased sensitivity for this mutant tumor. Thus, novel treatment strategies including T790M-targeting drugs are required to improve the efficacy of EGFR-TKIs in this population. Background It has been reported that the presence of pretreatment EGFR T790M mutation may reduce the efficacy to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant lung cancer. However, clinicopathologic features related to the likelihood of T790M mutation before treatment remains unknown. Patients and Methods DNA from 124 pretreatment tissue samples from patients with advanced non-small cell lung cancer carrying sensitive EGFR mutations was genotyped for EGFR T790M mutation with mass spectrometry. We compared the characteristics of 24 T790M patients and 100 patients with no or a low-level T790M mutation. Results There were no differences in age, sex, histology, or initial stage between T790M and non/low T790M groups. However, there were significantly more never-smokers in the T790M group (P = 0.017). Brain metastasis was also more common in the T790M group (P = 0.036). The response rates to platinum, taxane, gemcitabine, and pemetrexed did not differ between the two groups. In the T790M group, the response rates were not significantly different among the four cytotoxic drugs (P = 0.809). The median time to progression during EGFR-TKI therapy was shorter in the T790M group than in the non/low T790M group (4.1 vs 11.5 months, respectively; P < 0.001). The median overall survival from the start of first-line treatment of advanced disease was similar in both groups (31.5 vs 36.0 months, respectively; P = 0.310). Conclusions The clinical features of EGFR T790M-mutant lung cancer were similar to those of sensitive EGFR-mutant lung cancer, except for the overrepresentation of never smokers and brain metastasis.
    Clinical Lung Cancer 09/2014; · 2.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Author Summary BACKGROUND: The efficacy of ventriculolumbar perfusion (VLP) chemotherapy with methotrexate (MTX) was evaluated for treatment of leptomeningeal carcinomatosis (LMC).
    The Oncologist 09/2014; · 4.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Levodopa (l-dopa) therapy in Parkinson's disease (PD) increases serum homocysteine levels because of its metabolism via catechol O-methyltransferase, which may lead to endothelial dysfunction.Method We enrolled 40 PD patients treated with l-dopa, 33 PD patients treated with l-dopa/entacapone, 22 untreated PD and 30 controls, and compared the flow-mediated dilation in these subjects.ResultsThe flow-mediated dilation was significantly lower in PD patients with l-dopa (6.0 ± 1.8%) than in those with l-dopa/entacapone (7.2 ± 1.1%, P = 0.03), untreated PD patients (7.8 ± 1.2%, P < 0.05), and controls (8.5 ± 2.9%, P < 0.05). The homocysteine level was significantly higher in PD patients with l-dopa than in other groups. In a multivariate logistic regression model, the uppermost homocysteine quartile was an independent predictor of the lowest tertile of flow-mediated dilation (odds ratio, 6.33; 95% confidence interval, 1.61-26.65; P = 0.012).Conclusions Our findings indicate that endothelial dysfunction may be associated with chronic l-dopa treatment in patients with PD. © 2014 International Parkinson and Movement Disorder Society
    Movement Disorders 08/2014; · 5.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the feasibility of high-resolution MRI (HR-MRI) for diagnosing intracranial vertebrobasilar artery dissection (VBD) and to identify the most useful imaging findings suggesting dissection.
    European Radiology 07/2014; · 4.34 Impact Factor
  • Source
    Jin Soo Lee, Hong Gyun Lee
    [Show abstract] [Hide abstract]
    ABSTRACT: Weakening of trunk muscles in stroke patients hinders functional ability, safety and balance. To confirm whether strengthening trunk muscles could facilitate rehabilitation of stroke patients, we investigated the effectiveness of sling exercise therapy (SET) using closed kinetic chain exercises to activate trunk muscles and improve balance in stroke patients. [Subjects and Methods] Twenty stroke patients with chronic hemiplegia were equally divided into 2 groups, a SET group and a control group that performed regular exercises on a mat with the assistance of a table. Patients in both groups exercised for 30 min, three times per week for 4 weeks. Trunk muscle activity was measured using surface electromyography, whereas balance was measured using the Berg Balance Scale, Frailty and Injuries Cooperative Studies of Intervention Technique, Timed Up & Go test, and BioRescue before and after the 4-week experimental period. [Results] Trunk muscle activity and balance before and after intervention in both groups were significantly different. However, no significant differences were observed between the 2 groups. [Conclusion] Although SET was not more effective than regular exercise, significant improvement was observed before and after SET. Therefore, SET can be considered effective in strengthening trunk muscles in stroke patients with chronic hemiplegia.
    Journal of Physical Therapy Science 05/2014; 26(5):655-9. · 0.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Postoperative recurrence in stage I non-small cell lung cancer (NSCLC) is the major cause of a poor prognosis. This study aims to identify genetic variants that associated with the prognosis of early stage NSCLC. A genome-wide association study (GWAS) was conducted in 250 patients in stage I NSCLC and the results were replicated in additional 308 patients. Results from an Affymetrix Genome-wide Human SNP array in 250 patients identified 94 single nucleotide polymorphisms (SNPs) with significant associations (p < 2×10(-4)), which were selected for replication in 308 additional patients. Pooled analysis of the 558 patients determined that rs1454694 in chromosome 4q34 was the most significant marker of lung cancer prognosis in this stage I patients (adjusted hazard ratio (HR) = 2.81; p = 5.91×10(-8)). After mapping the candidate loci, an additional four markers at chromosome 4q34.3 were significantly associated with recurrence-free survival (RFS) (p < 5×10(-5)). A haplotype of five SNPs in 4q34 also showed significant association with RFS (p = 4.29×10(-6)). A genetic polymorphism, rs1454694 was identified as a novel genetic risk factor for recurrence free survival of stage I NSCLC. This genome-wide study suggests that genetic markers in 4q34.3 contribute to predict the prognosis of Korean patients with stage I NSCLC.
    Clinical Cancer Research 04/2014; · 8.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stomach cancer is the third deadliest among all cancers worldwide. Although incidence of the intestinal-type gastric cancer has decreased, the incidence of diffuse-type is still increasing and its progression is notoriously aggressive. There is insufficient information on genome variations of diffuse-type gastric cancer because its cells are usually mixed with normal cells, and this low cellularity has made it difficult to analyze the genome. We analyze whole genomes and corresponding exomes of diffuse-type gastric cancer, using matched tumor and normal samples from 14 diffuse-type and five intestinal-type gastric cancer patients. Somatic variations found in the diffuse-type gastric cancer are compared to those of the intestinal-type and to previously reported variants. We determine the average exonic somatic mutation rate of the two types. We find associated candidate driver genes, and identify seven novel somatic mutations in CDH1, which is a well-known gastric cancer-associated gene. Three-dimensional structure analysis of the mutated E-cadherin protein suggests that these new somatic mutations could cause significant functional perturbations of critical calcium-binding sites in the EC1-2 junction. Chromosomal instability analysis shows that the MDM2 gene is amplified. After thorough structural analysis, a novel fusion gene TSC2-RNF216 is identified, which may simultaneously disrupt tumor-suppressive pathways and activate tumorigenesis. We report the genomic profile of diffuse-type gastric cancers including new somatic variations, a novel fusion gene, and amplification and deletion of certain chromosomal regions that contain oncogenes and tumor suppressors.
    Genome biology 04/2014; 15(4):R55. · 10.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND Epidermal growth factor receptor (EGFR) T790M mutation drives acquired drug resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR-mutant lung cancer. However, it was reported that this mutation may exist before drug exposure. The objective of the current study was to evaluate whether the clinical outcomes are affected by the percentage of preexisting T790M mutations within a tumor.METHODS Pretreatment tissues were collected from 124 patients with advanced non-small cell lung cancer with sensitizing EGFR mutations that were detected by direct sequencing. Genotyping for EGFR T790M mutation was further performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Patients who were positive for the T790M mutation were divided to 2 subgroups according to T790M mutant signal frequency.RESULTSThe T790M mutation was found in 31 patients (25.0%). The T790M mutation frequency at which the risk of disease progression after therapy with EGFR-TKIs begins to increase was estimated to be 3.2%. The patients with T790M-positive tumors had a shorter time to disease progression after treatment with EGFR-TKIs (median, 6.3 months vs 11.5 months; P < .001) and overall survival (median, 16.1 months vs 26.5 months; P = .065) compared with those with T790M-negative tumors. Among the T790M-positive patients, the patients with high T790M frequency (9 patients) were found to have a shorter time to disease progression (median, 2.4 months vs 6.7 months; P = .009) and overall survival (median, 9.1 months vs 18.7 months; P = .018) compared with those with low T790M frequency (22 patients).CONCLUSIONSA preexisting EGFR T790M mutation was noted in 25% of patients with EGFR-mutant lung cancer. Patients with a high T790M mutation frequency had worse clinical outcomes to EGFR-TKIs than patients with a low T790M mutation frequency. Cancer 2014. © 2014 American Cancer Society.
    Cancer 04/2014; · 5.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Functional versatility and elevated expression in cancers have endowed p21-activated kinase 4 (PAK4) as one of the first-in-class anti-cancer drug target. In this study, a novel PAK4 inhibitor, KY-04031 (N(2)-(2-(1H-indol-3-yl)ethyl)-N(4)-(1H-indazol-5-yl)-6-methoxy-1,3,5-triazine-2,4-diamine), was discovered using a high-throughput screening. Analysis of the complex crystal structure illustrated that both indole and indazole of KY-04031 are responsible for PAK4 hinge interaction. Moreover, the molecule's triazine core was found to mimic the ribose of the natural ATP substrate. The cell-based anti-cancer potency of KY-04031 was less effective than the pyrroloaminopyrazoles; however, the unique molecular feature of KY-04031 can be exploited in designing new PAK4 inhibitors.
    Cancer letters 04/2014; · 5.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background/Aims: To better understand potential risks for vertebral artery (VA) dissection (VAD), we compared intracranial and extracranial VADs. Methods: We analyzed consecutively admitted VAD patients over a 9-year period in whom VAD was confirmed by angiography. All patients were categorized as having intracranial or extracranial VAD, and demographic and radiological characteristics of VAD were compared. We used multivariate analysis to predict the risks for intracranial and extracranial VADs. Results: The study population (n = 74) had a mean age of 46.0 ± 10.3 years. VAD was more frequent in the nondominant VA (n = 49, 66.2%). Vertical nidus of VAD was more common in the intracranial segment (81.1%), and more particularly it was most frequently located within a 2-mm perimeter of the posterior inferior cerebellar artery (PICA) orifice (60.0%). Absence of traumatic history (OR 13.1, 95% CI 1.6-107.4; p = 0.016), history of hypertension (OR 14.1, 95% CI 1.1-184.6; p = 0.043) and aging (OR 1.1 per 1-year increase, 95% CI 1.0-1.2; p = 0.038) were independent predictors of intracranial VAD. Conclusion: As compared to extracranial VAD, intracranial VAD was particularly frequent and particularly vulnerable at the perimeters of the PICA and nondominant VA and was associated with an absent trauma history, hypertension and aging. Formation of VAD appeared to be different according to intracranial or extracranial involvement. © 2014 S. Karger AG, Basel.
    European Neurology 03/2014; 71(5-6):305-312. · 1.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aims to identify clinical case definitions of influenza with higher accuracy in patients stratified by age group and influenza activity using hospital-based surveillance system. In seven tertiary hospitals across South Korea during 2011-2012 influenza season, respiratory specimens were obtained from patients presenting an influenza-like illness (ILI), defined as having fever plus at least one of following symptoms: cough, sore throat or rhinorrhea. Influenza was confirmed by reverse transcriptase-polymerase chain reaction. We performed multivariate logistic regression analyses to identify clinical variables with better relation with laboratory-confirmed influenza, and compared the accuracy of combinations. Over the study period, we enrolled 1417 patients, of which 647 had laboratory-confirmed influenza. Patients with cough, rhinorrhea, sore throat or headache were more likely to have influenza (p<0.05). The most accurate criterion across the study population was the combination of cough, rhinorrhea, sore throat and headache (sensitivity 71.3%, specificity 60.1% and AUROC 0.66). The combination of rhinorrhea, sore throat and sputum during the peak influenza activity period in the young age group showed higher accuracy than that using the whole population (sensitivity 89.3%, specificity 72.1%, and AUROC 0.81). The accuracy of clinical case definitions of influenza differed across age groups and influenza activity periods. Categorizing the entire population into subgroups would improve the detection of influenza patients in the hospital-based surveillance system.
    PLoS ONE 01/2014; 9(1):e84873. · 3.53 Impact Factor
  • Source
    Journal of stroke. 01/2014; 16(1):51-3.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and Purpose—Therapeutic hypothermia improves outcomes in experimental stroke models, especially after ischemia-reperfusion injury. We investigated the clinical and radiological effects of therapeutic hypothermia in acute ischemic stroke patients after recanalization. Methods—A prospective cohort study at 2 stroke centers was performed. We enrolled patients with acute ischemic stroke in the anterior circulation with an initial National Institutes of Health Stroke Scale ≥10 who had successful recanalization (≥thrombolysis in cerebral ischemia, 2b). Patients at center A underwent a mild hypothermia (34.5°C) protocol, which included mechanical ventilation, and 48-hour hypothermia and 48-hour rewarming. Patients at center B were treated according to the guidelines without hypothermia. Cerebral edema, hemorrhagic transformation, good outcome (3-month modified Rankin Scale, ≤2), mortality, and safety profiles were compared. Potential variables at baseline and during the therapy were analyzed to evaluate for independent predictors of good outcome. Results—The hypothermia group (n=39) had less cerebral edema (P=0.001), hemorrhagic transformation (P=0.016), and better outcome (P=0.017) compared with the normothermia group (n=36). Mortality, hemicraniectomy rate, and medical complications were not statistically different. After adjustment for potential confounders, therapeutic hypothermia (odds ratio, 3.0; 95% confidence interval, 1.0–8.9; P=0.047) and distal occlusion (odds ratio, 7.3; 95% confidence interval; 1.3–40.3; P=0.022) were the independent predictors for good outcome. Absence of cerebral edema (odds ratio, 5.4; 95% confidence interval, 1.6–18.2; P=0.006) and no medical complications (odds ratio, 9.3; 95% confidence interval, 2.2–39.9; P=0.003) were also independent predictors for good outcome during the therapy. Conclusions—In patients with ischemic stroke, after successful recanalization, therapeutic hypothermia may reduce risk of cerebral edema and hemorrhagic transformation, and lead to improved clinical outcomes
    Stroke 01/2014; · 6.02 Impact Factor
  • Source
    The Korean Journal of Internal Medicine 01/2014; 29(1):132-47.
  • Korean Journal of Medicine. 01/2014; 86(3):367.

Publication Stats

4k Citations
825.61 Total Impact Points

Institutions

  • 2003–2014
    • National Cancer Center Korea
      • • Specific Organs Cancer Branch
      • • Lung Cancer Branch
      Kōyō, Gyeonggi Province, South Korea
    • Ajou University
      • Department of Neurology
      Sŏul, Seoul, South Korea
  • 2013
    • Catholic University of Korea
      • Department of Internal Medicine
      Seoul, Seoul, South Korea
    • Yonsei University
      Sŏul, Seoul, South Korea
    • University of Texas Health Science Center at Houston
      Houston, Texas, United States
  • 2012–2013
    • Yonsei University Hospital
      • Department of Internal Medicine
      Seoul, Seoul, South Korea
    • Seoul National University Bundang Hospital
      • Department of Neurosurgery
      Seoul, Seoul, South Korea
    • Gachon University
      • Department of Neurology
      Seongnam, Gyeonggi, South Korea
  • 2007–2013
    • Inha University Hospital
      Sinhyeon, South Gyeongsang, South Korea
    • Seoul National University
      • Cancer Research Institute
      Seoul, Seoul, South Korea
    • Sookmyung Women's University
      • College of Pharmacy
      Seoul, Seoul, South Korea
  • 2005–2013
    • Inha University
      • Department of Family Medicine
      Chemulpo, Incheon, South Korea
  • 2011
    • Yale University
      • Department of Internal Medicine
      New Haven, CT, United States
    • Ewha Womans University
      Sŏul, Seoul, South Korea
  • 2010
    • Hallym University Medical Center
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea
  • 1999–2010
    • Korea Research Institute of Chemical Technology
      Daiden, Daejeon, South Korea
  • 2008
    • University of Ulsan
      • Department of Internal Medicine
      Ulsan, Ulsan, South Korea
    • Gyeongsang National University
      • Department of Neurosurgery
      Chinju, South Gyeongsang, South Korea
  • 2006
    • Asan Medical Center
      • Department of Oncology
      Seoul, Seoul, South Korea
  • 1999–2006
    • University of Texas MD Anderson Cancer Center
      • Department of Thoracic Head Neck Medical Oncology
      Houston, Texas, United States
  • 2003–2005
    • Chonbuk National University
      • Department of Organic Materials and Fiber Engineering
      Seoul, Seoul, South Korea
  • 2004
    • Kyung Hee University
      • Advanced Display Research Center
      Sŏul, Seoul, South Korea